Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Unity Software Inc (U) Price & Performance

Amylx Pharmaceuticals IncTrade
Unity Software IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Unity Software Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Unity Software Inc trades at $43.68 (market cap $18.97B). The key difference: Unity Software Inc is far larger — about 7.5× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Unity Software Inc nearer its low. Which is the better fit depends on your goals.

AMLXU
Market Cap
$2.53B$18.97B
Sector
HealthTechnology
52-Week High
$24.19$49.47
52-Week Low
$7.82$17.13
Enterprise Value
$2.28B$18.85B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Unity Software Inc

Unity Software (U) trades at $43.00, up 5.37% today, with strong technical momentum and bullish analyst sentiment. The stock shows improving fundamentals with Q2 2026 earnings beating expectations, revenue growth of 24% year-over-year, and narrowing losses. Recent news highlights Vector advertising platform momentum and accelerated AI integration driving optimism.

The outlook remains positive with 69% analyst buy ratings and $47.45 consensus price target, though risks include persistent net losses, high valuation multiples, and competitive pressures. Continued execution on profitability timeline and Vector platform growth are key catalysts for further upside potential.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Unity Software Inc

Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.

Read more on U